Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) EBITDA Margin: 2009-2024

Historic EBITDA Margin for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to 14.76%.

  • OptimizeRx's EBITDA Margin rose 480400.0% to 7.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.17%, marking a year-over-year increase of 382000.0%. This contributed to the annual value of 14.76% for FY2024, which is 220200.0% up from last year.
  • Latest data reveals that OptimizeRx reported EBITDA Margin of 14.76% as of FY2024, which was up 220200.0% from 36.77% recorded in FY2023.
  • OptimizeRx's 5-year EBITDA Margin high stood at 0.76% for FY2021, and its period low was 36.77% during FY2023.
  • Its 5-year average for EBITDA Margin is 15.0%, with a median of 14.76% in 2024.
  • Per our database at Business Quant, OptimizeRx's EBITDA Margin plummeted by -203000bps in 2022 and then soared by 220200bps in 2024.
  • Annual analysis of 5 years shows OptimizeRx's EBITDA Margin stood at 4.71% in 2020, then soared by 116bps to 0.76% in 2021, then crashed by -2668bps to 19.54% in 2022, then crashed by -88bps to 36.77% in 2023, then soared by 60bps to 14.76% in 2024.
  • Its EBITDA Margin stands at 14.76% for FY2024, versus 36.77% for FY2023 and 19.54% for FY2022.